Endoleaks Type II: no association with mortality

Original Title: Risk factors and consequences of persistent type II endoleaks. Reference: Ruby C. Lo et al. J Vasc Surg 2016;63:895-901

 

The presence of type II endoleaks is infrequent (1%-10%) and most cases resolve spontaneously at 12 months. When they don’t, there is still controversy as to whether they may be associated to aneurysm diameter increase or to aneurysm rupture requiring intervention or conversion to surgery.

2367 patients receiving endovascular aneurysm repair were analyzed; 1977 (84%) did not present leaks or presented transient endoleaks, and 390 patients presented persistent endoleaks at follow up.

There were no differences in anatomical characteristics of aneurysms between those with endoleaks and those without.

There were no difference in device type, but there was a higher rate of type II endoleaks with coil embolization to one or both hypogastric arteries (12% vs. 8% p=0.02) and also a higher rate of endoleaks when using extensions (12% vs. 8% (p=0.008).

Follow up was at mean 463 days and the presence of type II endoleaks was a predictor of reintervention (OR 15.3; CI 95% 9.7-24.3; p<0.01) but not of mortality (OR 1.1; CI 95% 0.9-1.6; p=0.477).

Conclusion
The presence of type II endoleaks in patients undergoing endovascular aneurysm repair to treat an abdominal aortic aneurysm is more frequent when there is coil embolization to one or both hypogastric arteries and when using extensions. Type II endoleak persistence is associated to an increase in reintervention but not to aneurysm rupture or mortality. This reinforces the need to control patients with type II endoleak persistence.

Editorial Comment
Though retrospective, and therefore weak, this is the largest study on type II endoleaks. Even so, it seems clear that type II endoleaks are not associated with hard events such as death or rupture.

Courtesy of Dr. Carlos Fava.
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...